Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Target Price at $11.50

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have earned a consensus recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.50.

A number of research analysts have recently weighed in on the company. UBS Group restated a “buy” rating and set a $7.00 price objective (down previously from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, November 11th. B. Riley reduced their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, BTIG Research started coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target on the stock.

Perspective Therapeutics Price Performance

CATX stock opened at $3.79 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.16. The business has a 50 day simple moving average of $2.63 and a two-hundred day simple moving average of $3.13.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, November 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. As a group, equities analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Trueblood Wealth Management LLC raised its position in Perspective Therapeutics by 210.6% during the second quarter. Trueblood Wealth Management LLC now owns 69,061 shares of the company’s stock valued at $238,000 after purchasing an additional 46,825 shares during the period. Nicholson Wealth Management Group LLC lifted its position in Perspective Therapeutics by 0.3% in the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after buying an additional 5,000 shares during the last quarter. Ground Swell Capital LLC purchased a new position in Perspective Therapeutics during the second quarter worth $56,000. Los Angeles Capital Management LLC bought a new position in Perspective Therapeutics during the second quarter valued at $61,000. Finally, Geode Capital Management LLC increased its position in Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.